{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:07:56Z","timestamp":1792516076515,"version":"4.5.0"},"reference-count":13,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Aberrations involving the\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      gene have not been reported in thyroid cancer. Here, a case of\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      -associated thyroid cancer with unique and aggressive characteristics is presented.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient findings:<\/jats:title>\n                    <jats:p>\n                      A 24-year-old athlete presented with a 3.5\u2009cm left paramedian upper neck mass. Open biopsy demonstrated a papillary thyroid carcinoma arising in the pyramidal lobe. Additional imaging revealed involvement of her cricothyroid membrane, thyroid laryngeal cartilage, and left vocal cord. Complete\n                      <jats:italic toggle=\"yes\">en bloc<\/jats:italic>\n                      surgical resection of the thyroid with cricothyroid membrane and endolarynx was performed with negative surgical margins. Microscopically, the tumor was largely solid with microfollicular architecture with focal cytoplasmic clearing and nodular invasion with rare true papillae, extending posteriorly through the cricothyroid membrane into the deep soft tissue of the left anterior vocal cord (pT4a). Metastases were present in 5\/11 lateral neck and pretracheal lymph nodes with a size up to 0.4\u2009cm (pN1b) with perinodal lymphatic involvement. She was staged according to her age (&lt;45 years) as stage I. The solid-variant histology and locally aggressive behavior triggered oncologic genotyping, which was performed using massive parallel sequencing and anchored multiplexed next-generation sequencing for gene fusion detection on formalin-fixed paraffin embedded tissue. Targeted genotyping did not reveal a panel-specific point mutation. However, gene fusion assessment demonstrated a gene fusion involving\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      . Mapping of the fusion and sequence analysis identified\n                      <jats:italic toggle=\"yes\">CCDC30<\/jats:italic>\n                      as the\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      fusion partner. Sequence-based prediction of the fusion product revealed the\n                      <jats:italic toggle=\"yes\">coiled-coil domain 30<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">CCDC30<\/jats:italic>\n                      ) gene fused to the\n                      <jats:italic toggle=\"yes\">N-terminal ROS1 kinase<\/jats:italic>\n                      domain, with CCDC30 as the postulated driver of ROS1-kinase constitutive activation.\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      rearrangement was confirmed using fluorescent\n                      <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                      hybridization as an orthogonal method. A review of all currently reported\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      fusions in &gt;7000 samples (The Cancer Genome Atlas) showed no prior report of\n                      <jats:italic toggle=\"yes\">ROS1-CCDC30<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      fusions, or presence of\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      aberrations in thyroid cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary:<\/jats:title>\n                    <jats:p>\n                      Herein, the first case of a\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      rearrangement in a papillary thyroid carcinoma with a locally aggressive presentation is reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      A review of additional patients with solid-variant papillary thyroid carcinoma and similar clinical characteristics with undetermined tumor genetics is needed, especially in light of the availability of\n                      <jats:italic toggle=\"yes\">ROS1<\/jats:italic>\n                      -targeted therapeutics.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2016.0101","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T21:57:24Z","timestamp":1461016644000},"page":"794-797","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["<i>ROS1<\/i>\n                    Rearrangement in Thyroid Cancer"],"prefix":"10.1177","volume":"26","author":[{"given":"Lauren L.","family":"Ritterhouse","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori J.","family":"Wirth","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Randolph","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"},{"name":"Massachusetts Eye and Ear Infirmary and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"},{"name":"Massachusetts Eye and Ear Infirmary and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Liddy","sequence":"additional","affiliation":[{"name":"Massachusetts Eye and Ear Infirmary and Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen K.","family":"Lennerz","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital\/Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5846"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005467"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2009.0110"},{"key":"e_1_3_2_6_2","first-page":"265","article-title":"The treatment landscape in thyroid cancer: a focus on cabozantinib","volume":"7","author":"Weitzman SP","year":"2015","unstructured":"Weitzman SP, , Cabanillas ME. 2015. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res, 7:265\u2013278.","journal-title":"Cancer Manag Res"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3729"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv362"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2148-5-66"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200112000-00002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2611"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0573"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.6345"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2016.0101","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2016.0101","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2016.0101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:13:54Z","timestamp":1779434034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2016.0101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1089\/thy.2016.0101"],"URL":"https:\/\/doi.org\/10.1089\/thy.2016.0101","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}